Indian pharma company Cipla has made another play in the digital medicine category by taking a near-12% stake in start-up Wellthy Therapeutics. Under the terms of their agreement Wellthy and Cipla ...

After topping the Street's expectations with its Q3 earnings, Cipla announced plans to launch two key drugs in FY26—the respiratory drug Advair and the oncology drug Abraxane. Umang Vohra ...

Cipla Q3 Results: Pharmaceutical major Cipla on Tuesday reported a 49 per cent year-on-year (YoY) increase in its consolidated net profit for the December quarter (Q3 FY25) at Rs 1,574.6 crore, from ...

Pharma major Cipla Ltd on Tuesday posted its highest-ever quarterly revenue and Ebitda margin, as robust sales in India, Europe and emerging markets outweighed weakness in its US business.

Cipla, one of the leading pharmaceutical companies in India, released its December quarter numbers (Q3FY25) on Tuesday, January 28, reporting a 48% year-on-year (YoY) jump in its consolidated net ...

Among other big names, Cipla slipped by eight places despite its performance in its core therapeutics business. However, its strategic investments in chronic therapy markets in the US and Africa ...

Cipla, Lupin deny in stake sale talks with Takeda Pharma Pharmaceutical companies Cipla and Lupin have both strongly denied that they are in talks with Takeda Pharmaceutical Co to sell stake or ...